FDA Approval for Pediatric Crohn's
The FDA approved Stelara (ustekinumab) in 2023 for children 6 years and older with moderately to severely active Crohn's disease who have had an inadequate response to or intolerance of conventional therapy or TNF-alpha antagonists.[1] This approval followed a Phase 3 UNIFI study extension showing efficacy in maintaining clinical remission and response in patients as young as 6, with dosing adjusted by weight (e.g., intravenous induction at 3-6 mg/kg, subcutaneous maintenance at 90 mg every 8 weeks for those ≥40 kg).[1][2]
Safety Profile in Kids
In pediatric Crohn's patients from the UNIFI trial (52 children aged 6-17), Stelara showed a safety profile consistent with adults: serious adverse events occurred in 15.4% of kids versus 17.6% in adults, with common issues like upper respiratory infections (13.5%), nasopharyngitis (9.6%), and abdominal pain (7.7%). No new safety signals emerged specific to children, and rates of serious infections or malignancies aligned with adult data.[2][3] Long-term data remains limited, with ongoing monitoring for rare risks.
Common Side Effects Patients Report
Kids on Stelara most often experience mild infections (e.g., colds, sinus issues), headaches, fatigue, and injection-site reactions. In trials, 3.8% discontinued due to adverse events, mainly worsening Crohn's symptoms. Hypersensitivity reactions are rare but monitored.[2]
Serious Risks and Warnings
Black-box warnings match adults: increased infection risk (including tuberculosis; screening required), potential malignancy (e.g., skin cancer with long-term use), and reversible posterior leukoencephalopathy syndrome. Live vaccines are contraindicated; non-live vaccines should precede treatment. No pediatric-specific cancer signals in trials, but data is from ~1 year median exposure.[1][3] Contraindicated in active severe infections.
How It Compares to Other Pediatric Options
| Drug | Age Approval | Common Pediatric Risks | Remission Rates (Pediatric Trials) |
|------|--------------|------------------------|------------------------------------|
| Stelara | ≥6 years | Infections (15%), similar to adults | 55-70% at week 52[2] |
| Infliximab (Remicade) | ≥6 years | Infusion reactions (20%), antibodies | 50-60%[4] |
| Adalimumab (Humira) | ≥6 years | Injection reactions (10-15%), infections | 40-60%[4] |
Stelara offers subcutaneous convenience post-induction, with potentially fewer immunogenicity issues than TNF drugs.[3]
Who Should Avoid It
Not for kids under 6, those with active infections, or recent live vaccines. Use caution in immunocompromised patients or with hepatotoxicity history. Pregnancy registry exists for adolescent females.[1]
When Does Treatment Start and Monitoring Look Like
Initiation involves TB screening, vaccines, and IV induction, followed by home subcutaneous doses. Pediatric gastroenterologists monitor with blood tests (e.g., CBC, LFTs) every 8-12 weeks initially, plus endoscopy if needed. Response assessed at week 8; switch therapies if no improvement.[2]
[1]: FDA Stelara Label
[2]: UNIFI Pediatric Data (JAMA)
[3]: Stelara Prescribing Info (Janssen)
[4]: Crohn's & Colitis Foundation Guidelines